Dana-Farber Cancer Institute, Astellas to research and develop small molecule inhibitors of oncogenic K-Ras – Pharmaceutical Business Review
0“Dana-Farber Cancer Institute and Astellas Pharma has announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.”
Read more – Pharmaceutical Business Review